Type 2 Diabetes Mellitus Clinical Trial
Official title:
Cut Down on Carbohydrate Usage in the Diet of Type 2 Diabetes; Mechanisms of Effective Therapy of Diabetes by Selective Choice of Macronutrients. The Isoenergetic Study.
Scientific evidence for the dietary treatment of type 2 diabetes (T2D) is insufficient. The study group hypothesizes that a lower carbohydrate content in the diabetic diet than the recommended 55 energy percentage (E%) will decrease the postprandial glucose excursion. This will reduce postprandial insulin concentration, which together with lower glucose concentration leads to less fat accumulation in the liver and muscle tissue, resulting in an improved insulin sensitivity which together with a reduced glucose load improves the glucose metabolism. This clinical study will examine in subjects with type 2 diabetes the effect of highly controlled dietary low carbohydrate intervention on metabolic pathways with respect to insulin action, pancreatic islet function, lipid metabolism, ectopic fat accumulation, incretin hormones, low grade inflammation in plasma and adipose tissue, novel measures of fatty acid metabolism, and heart rate variability, respectively. The studies exhibit the potential to reform dietary recommendation aiming to prevent and ameliorate type 2 diabetes.
The study will be performed as a randomized 12 weeks controlled, cross-over trial, which will
address the effects on T2D of an isoenergetic low carbohydrate diet (carbohydrate 30 E%,
protein 30 E%, fat 40 E%) compared to an isoenergetic control diet (carbohydrate 50 E%,
protein 17 E%, fat 33 E%) currently recommended to individuals with T2D. The study is
extended with 24 weeks on an isoenergetic low carbohydrate diet to examine the prolonged
effect of the experimental diet on T2D and its pathophysiology. To test the hypothesis that
the isoenergetic control diet is detrimental to glucose metabolism after only a short
transition to this diet, the participants are reinforced to eat that diet during 6 weeks
after the 24 weeks on low carbohydrate/high protein diet.
The study includes n=30 subjects with T2D. All study participants will be provided all meals
for both the low carbohydrate diet and the control diet for free in the first part of the
study, i.e. week 0 to 12, and these food items will be prepared and distributed from the
research kitchen of the Department of Nutrition, Exercise and Sports, Faculty of Science,
University of Copenhagen, Denmark to optimize compliance and adherence to the prescriped
diet. During the isoenergetic diet study weight stability is reinforced to facilitate
interpretation of the diet effect. All diets will be isoenergetic in accordance with the
participant's estimated daily total energy expenditure (TEE). A dual energy X-ray
absorptiometry (DXA) scan will be undertaken to determine body composition for each
participant in order to estimate daily resting energy expenditure (REE). To estimate TEE,
physical activity level expressed as PAL = TEE / REE, will be estimated. If a participant
develops weight loss or weight gain at three consecutive measurements and/or lose or gain >
1kg of weight compared to baseline, the amount of energy in the diet wil be adjusted
accordingly to enforce weight stability throughout the full duration of the study.
Measurements includes glycated hemoglobin (HbA1c) and fasting glucose, insulin, C-peptide and
non-esterified fatty acids (NEFA) every 2 weeks during the first 12 weeks of the study and
every 4 weeks from week 12.
At baseline, week 6, 12, 36 and 42, respectively larger measurement programs will be
undertaken including insulin modified frequently sampled intravenous glucose tests (IM-FSIGT)
and meal tests by use of Minimal Modelling, magnetic resonance imaging (MRi) for fat content
in liver, abdomen and muscle, adipose tissue biopsies, continous glucose monitoring for
48-hours including diurnal blood pressure and Holter recording.
A standard meal will be provided for dinner a day prior to the measurement programs at week
0, 36 and 42. At weeks 6 and 12 the participants will intake their assigned meals.
Participants will be informed to refrain from any strenuous physical activity and alcohol
intake two days prior to and during the measurement program days.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
Completed |
NCT02226003 -
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
|
Phase 3 |